1.85
+2.78%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Cuprina Holdings (Cayman)
Its shares trade under the ticker CUPR. It has been listed since 10 April 2025. In the fiscal year to 31 December 2025, it reported revenue of SGD 49,894 and a net loss of SGD 4.7m. At that date it held total assets of SGD 8.5m and shareholders' equity of SGD 5.1m.
Cuprina Holdings (Cayman) Ltd. engages in the manufacturing, sale, and supply of medical devices to manage and accelerate healing and closure of chronic wounds. The company employs 14 full-time employees The company went IPO on 2025-04-10. The firm is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sectors. The firm manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy (MDT), which is an alternative to surgical debridement. The company also offers two lines of chronic wound care products in its pipeline. Such lines of pipeline chronic wound care products include Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus), and Products utilizing medical leeches for wound treatment.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 10 Apr 2025
- Employees
- 14
- Website
- cuprina.com ↗
- Head office
- BLOCK 1090, SINGAPORE, U0, 169201
- Incorporated in
- E9
- Classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Yong Qi QuekChief Executive Officer, Director
- Mr. Tat Jing ChanChief Financial Officer, since 2023
- Mr. Carl BaptistaChief Technology Officer, Director
- Mr. Peng Siew LeeNon-Executive Director
- Mr. Peng Kwang TeoNon-Executive Director
- Mr. Pee Keat KohIndependent Director
- Mr. Ivan NgIndependent Director
- Ms. Natasha RainaIndependent Director
- Mr. Scott PowellInvestor Relations, President, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Cuprina Holdings employs 14 full-time employees focused on medical device manufacturing and sales.
- Cuprina's MEDIFLY brand offers bio-dressing products for chronic wound management using sterile blowfly larvae.
- Cuprina's pipeline includes collagen dressings from bullfrog collagen and medical leech products for wound treatment.
Weaknesses
- Cuprina's IPO on April 10, 2025, indicates limited market presence and early-stage operations.
- Cuprina operates with a small team of 14 employees in a competitive health care sector.
- Cuprina's business is dedicated to chronic wound care, which has limited market size compared to broader health care segments.
Opportunities
- Cuprina's MEDIFLY products address the growing need for alternative wound care solutions like Maggot Debridement Therapy.
- Cuprina's pipeline of collagen dressings and leech-based products targets expanding chronic wound care markets.
- Cuprina can leverage bullfrog collagen from abattoir waste streams to create sustainable medical products.
Threats
- Cuprina faces competition from established medical device manufacturers in the health care sector.
- Cuprina's reliance on a single product line MEDIFLY may limit market diversification.
- Cuprina's small team size of 14 employees may hinder rapid scaling and innovation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.